Astra Zeneca reports profits boost
Anglo Swedish pharmaceuticals firm AstraZeneca reported a first quarter profit climb of 29 percent on Thursday on the back of a "strong" performance in emerging markets and sales of key products.
Net earnings leapt to $2.78 billion in the three months to the end of March, compared with the same part of 2009, AstraZeneca said in a statement on the report.
That easily beat market expectations for net profit of $2.15 billion, according to analysts polled by Dow Jones Newswires.
Turnover grew by 11 percent to $8.576 billion dollars during the reporting period, boosted by sales of key drugs like cholesterol drug Crestor, anti-psychotic drug Seroquel and asthma treatment Symbicort.
The pharmaceuticals group, which reports in dollars, was also aided by the US currency's strength during the latest quarter.
"The first quarter results reflect continued strong market performance for key brands like Crestor, Seroquel and Symbicort," said Chief Executive David Brennan said in the earnings release.
"We saw revenue growth in all major regions, including another strong quarter in emerging markets."
Earlier this week, meanwhile, AstraZeneca agreed to pay a $520 million fine to settle allegations it illegally marketed Seroquel for unapproved uses.
The firm's US division agreed to the fine for marketing Seroquel for so-called "off-label" uses not included in the drug's approved product label, the US Justice Department said.
US authorities contended that AstraZeneca illegally marketed Seroquel for uses never approved by the Food and Drug Administration such as aggression, Alzheimer's disease, anger management, anxiety, attention deficit hyperactivity disorder, bipolar maintenance, dementia, depression, mood disorder, post-traumatic stress disorder, and sleeplessness.
By doing so, the pharmaceutical group received government insurance payments that officials said were fraudulent.
Under the settlement terms, the federal government will receive some $301 million and various state insurance programs will get $218 million.
Comments
See Also
Net earnings leapt to $2.78 billion in the three months to the end of March, compared with the same part of 2009, AstraZeneca said in a statement on the report.
That easily beat market expectations for net profit of $2.15 billion, according to analysts polled by Dow Jones Newswires.
Turnover grew by 11 percent to $8.576 billion dollars during the reporting period, boosted by sales of key drugs like cholesterol drug Crestor, anti-psychotic drug Seroquel and asthma treatment Symbicort.
The pharmaceuticals group, which reports in dollars, was also aided by the US currency's strength during the latest quarter.
"The first quarter results reflect continued strong market performance for key brands like Crestor, Seroquel and Symbicort," said Chief Executive David Brennan said in the earnings release.
"We saw revenue growth in all major regions, including another strong quarter in emerging markets."
Earlier this week, meanwhile, AstraZeneca agreed to pay a $520 million fine to settle allegations it illegally marketed Seroquel for unapproved uses.
The firm's US division agreed to the fine for marketing Seroquel for so-called "off-label" uses not included in the drug's approved product label, the US Justice Department said.
US authorities contended that AstraZeneca illegally marketed Seroquel for uses never approved by the Food and Drug Administration such as aggression, Alzheimer's disease, anger management, anxiety, attention deficit hyperactivity disorder, bipolar maintenance, dementia, depression, mood disorder, post-traumatic stress disorder, and sleeplessness.
By doing so, the pharmaceutical group received government insurance payments that officials said were fraudulent.
Under the settlement terms, the federal government will receive some $301 million and various state insurance programs will get $218 million.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.